Evogene Email Format
Biotechnology ResearchCentral District, Israel51-200 Employees
Evogene Ltd. is a biotechnology research company based in Rehovot, Israel, focused on computational chemistry and the generative design of small molecules for pharmaceutical and agricultural applications. Its flagship platform, ChemPass AI, is a proprietary engine that designs novel molecules optimized across multiple parameters to improve success rates and shorten development timelines. The firm pursues a Real-World Innovation approach, aligning scientific advances with concrete industry needs through partnerships and internal product development. Its target markets include pharmaceutical and agricultural entities seeking faster, more cost-efficient development of small-molecule products. In June 2026, Evogene announced the successful completion of a first-in-human Phase 1 study of BMC128, a live bacterial product developed by its Biomica subsidiary, with favorable safety data and early signals of activity in combination with Nivolumab.